A One Year Study of the Macular Pigment: The Effect of 140 Days of a Lutein Supplement

Landrum, John T.; Bone, Richard A.; Joa, Hilda; Kilburn, Mark D.; Moore, Linda L.; Sprague, Kathleen E.

doi:10.1006/exer.1997.0309

Cited by 408 publications

(292 citation statements)

References 16 publications

Supporting

Mentioning

264

Contrasting

Unclassified

Order By: Relevance

“…Macular pigment optical density levels, however, remained largely unchanged over the six-month supplementation period. In other studies the retinal response has been reported to occur after 15 weeks with increased dietary levels of corn and spinach (Hammond et al, 1997), 140 days with 30 mg/day supplemental lutein or zeaxanthin, and 6 months with 2.4 mg/day supplemental lutein or zeaxanthin (Landrum, Bone et al, 1997). The response rates appear to be variable, and this may explain why we did not find an effect on CS.…”

Section: Discussionmentioning

confidence: 94%

“…There is evidence for selective deposition of lutein in the retina (Rapp et al, 2000, increase of retinal and serum levels of lutein with supplementation (Hammond et al, 1997;Landrum et al, 1997;Berendschot et al, 2000), and an increased risk of ARMD with low serum (EDCCS Group, 1993) and retinal (Beatty et al, 2001;Bone et al, 2001) lutein levels. Lutein/ zeaxanthin supplementation has been linked with improved visual function in patients with congenital retinal degenerations (Dagnelie et al, 2000) and with AMD (Richer, 1999).…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Effect of lutein and antioxidant dietary supplementation on contrast sensitivity in age-related macular disease: a randomized controlled trial

Bartlett

Eperjesi

2007

Eur J Clin Nutr

View full text Add to dashboard Cite

Objective: The aim of the study is to determine the effect of lutein combined with vitamin and mineral supplementation on contrast sensitivity in people with age-related macular disease (ARMD). Design: A prospective, 9-month, double-masked randomized controlled trial. Setting: Aston University, Birmingham, UK and a UK optometric clinical practice. Subjects: Age-related maculopathy (ARM) and atrophic age-related macular degeneration (AMD) participants were randomized (using a random number generator) to either placebo (n ¼ 10) or active (n ¼ 15) groups. Three of the placebo group and two of the active group dropped out. Interventions: The active group supplemented daily with 6 mg lutein combined with vitamins and minerals. The outcome measure was contrast sensitivity (CS) measured using the Pelli-Robson chart, for which the study had 80% power at the 5% significance level to detect a change of 0.3 log units. Results: The CS score increased by 0.0770.07 and decreased by 0.0270.18 log units for the placebo and active groups, respectively. The difference between these values is not statistically significant (z ¼ À0.903, P ¼ 0.376). Conclusion:The results suggest that 6 mg of lutein supplementation in combination with other antioxidants is not beneficial for this group. Further work is required to establish optimum dosage levels.

show abstract

Section: Discussionmentioning

confidence: 94%

Section: Discussionmentioning

confidence: 99%

Effect of lutein and antioxidant dietary supplementation on contrast sensitivity in age-related macular disease: a randomized controlled trial

Bartlett

Eperjesi

2007

Eur J Clin Nutr

View full text Add to dashboard Cite

show abstract

“…15 Hence, the amount of MP depends on the amount of lutein-and (meso)zeaxanthin-rich foods we ingest, and can be further influenced by the intake of nutritional supplements containing lutein and (meso)zeaxanthin. 2,16,17 Accurate assessment of the amount of MP, expressed as MP optical density (MPOD), is therefore necessary to investigate the role of carotenoids and their assumed protective functions. High repeatability and reliability are especially important to monitor patients in studies investigating the influence of diet and/or nutritional (lutein and (meso)zeaxanthin) supplements, or disease processes on MPOD.…”

Section: Introductionmentioning

confidence: 99%

Macular pigment optical density measurements: evaluation of a device using heterochromatic flicker photometry

Kinkelder

Veen

Verbaak

et al. 2010

Eye

View full text Add to dashboard Cite

Purpose Accurate assessment of the amount of macular pigment (MPOD) is necessary to investigate the role of carotenoids and their assumed protective functions. High repeatability and reliability are important to monitor patients in studies investigating the influence of diet and supplements on MPOD. We evaluated the Macuscope (Macuvision Europe Ltd., Lapworth, Solihull, UK), a recently introduced device for measuring MPOD using the technique of heterochromatic flicker photometry (HFP). We determined agreement with another HFP device (QuantifEye; MPS 9000 series: Tinsley Precision Instruments Ltd., Croydon, Essex, UK) and a fundus reflectance method. Methods The right eyes of 23 healthy subjects (mean age 33.9±15.1 years) were measured. We determined agreement with QuantifEye and correlation with a fundus reflectance method. Repeatability of QuantifEye was assessed in 20 other healthy subjects (mean age 32.1 ± 7.3 years). Repeatability was also compared with measurements by a fundus reflectance method in 10 subjects. Results We found low agreement between test and retest measurements with Macuscope. The average difference and the limits of agreement were À0.041 ± 0.32. We found high agreement between test and retest measurements of QuantifEye (À0.02±0.18) and the fundus reflectance method (À0.04±0.18). MPOD data obtained by Macuscope and QuantifEye showed poor agreement: À0.017 ± 0.44. For Macuscope and the fundus reflectance method, the correlation coefficient was r ¼ 0.05 (P ¼ 0.83). A significant correlation of r ¼ 0.87 (Po0.001) was found between QuantifEye and the fundus reflectance method. Conclusions Because repeatability of Macuscope measurements was low (ie, wide limits of agreement) and MPOD values correlated poorly with the fundus reflectance method, and agreed poorly with QuantifEye, the tested Macuscope protocol seems less suitable for studying MPOD.

show abstract

“…Landrum et al investigated the effect of lutein supplementation in two individuals over a 140 day period. 52 They found an increase in serum lutein levels in both individuals, coupled with a parallel increase in MP optical density. Interestingly, they also demonstrated maintenance of the interocular asymmetry of MP optical density in one of these individuals, suggesting that local retinal processes may play a role in the capture and stabilization of the xanthophyll carotenoids.…”

Section: Effect Of Lutein and Zeaxanthin Supplementation On The Retinamentioning

confidence: 93%

Transport and Retinal Capture of Lutein and Zeaxanthin with Reference to Age-related Macular Degeneration

Loane

Nolan

O'Donovan

et al. 2008

Survey of Ophthalmology

100

View full text Add to dashboard Cite

Abstract. Age-related macular degeneration (AMD) is the most common cause of irreversible blindness in the elderly population in the western world. The etiology and pathogenesis of this disease remain unclear. However, there is an increasing body of evidence supporting the hypothesis that the macular pigment carotenoids, lutein and zeaxanthin, play an important role in protection against AMD, by filtering out blue light at a pre-receptoral level, or by quenching free radicals. Lutein and zeaxanthin are dietary xanthophyll carotenoids, which are delivered to the retina via plasma lipoproteins. The biological mechanisms governing retinal capture and accumulation of lutein and zeaxanthin, to the exclusion of other carotenoids, are still poorly understood. Although these mechanisms remain unclear, it is possible that selective capture of these carotenoids is related to lipoprotein, or apolipoprotein, function and profile. Xanthophyll-binding proteins appear to play an important role in the retinal capture of the xanthophyll carotenoids. The Pi isoform of GSTP1 has been isolated as a specific binding protein for zeaxanthin. The binding protein responsible for retinal uptake of lutein remains elusive. This article reviews the literature germane to the mechanisms involved in the capture, accumulation and stabilization of lutein and zeaxanthin by the retina, and the processes involved in their transport in serum. (Surv Ophthalmol 53:68--81, 2008 The central retina, known as the macula, is responsible for central and color vision because of its high concentration of cone photoreceptors. The macula is characterized by a yellow color, attributable to the presence of macular pigment. 81 Macular pigment (MP) is composed of lutein and zeaxanthin, two hydroxycarotenoids, which are entirely of dietary origin. 17 The concentration of MP peaks at the center of the macula, known as the fovea, where zeaxanthin is the dominant carotenoid. In contrast, lutein dominates in the parafoveal region. 16,82 Dietary sources 68

show abstract

A One Year Study of the Macular Pigment: The Effect of 140 Days of a Lutein Supplement

Cited by 408 publications

References 16 publications

Effect of lutein and antioxidant dietary supplementation on contrast sensitivity in age-related macular disease: a randomized controlled trial

Effect of lutein and antioxidant dietary supplementation on contrast sensitivity in age-related macular disease: a randomized controlled trial

Macular pigment optical density measurements: evaluation of a device using heterochromatic flicker photometry

Transport and Retinal Capture of Lutein and Zeaxanthin with Reference to Age-related Macular Degeneration

Contact Info

Product

Resources

About